☆ 4.5 Article

Growth factors in tumor microenvironment

FRONTIERS IN BIOSCIENCE-LANDMARK (2010)

期刊

FRONTIERS IN BIOSCIENCE-LANDMARK

卷 15, 期 -, 页码 151-165

出版社

FRONTIERS IN BIOSCIENCE INC

DOI: 10.2741/3612

关键词

Tumor microenvironment; growth factor; EGFR; FGF; PDGF; Review

类别

Biochemistry & Molecular Biology Cell Biology

资金

NATIONAL CANCER INSTITUTE [R01CA131445] Funding Source: NIH RePORTER
NCI NIH HHS [R01 CA131445] Funding Source: Medline

向作者/读者索取更多资源

Protocol

Reagent

摘要

Tumor microenvironment plays a critical role in tumor initiation and progression. Components in the microenvironment can modulate the growth of tumor cells, their ability to progress and metastasize. A major venue of communication between tumor cells and their microenvironment is through polypeptide growth factors and receptors for these growth factors. This article discusses three major classes of growth-stimulatory polypeptide growth factors and receptors for these growth factors. It also discusses how deregulation of these growth factors or their receptors can drive malignant transformation and progression.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Biochemistry & Molecular Biology

A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions

Selvaraj Vimalraj

Summary: Angiogenesis is the formation of new blood vessels from existing ones. Abnormal angiogenesis, seen in tumor microenvironments, is characterized by distorted and leaky blood vessels with various shapes and high perfusion efficiency. Tumor angiogenesis plays a crucial role in cancer growth, invasion, and metastasis, and is tightly regulated by signaling networks. Targeting multiple signaling pathways involved in angiogenesis is important for effective antiangiogenic therapy. New therapeutic approaches, such as blocking specific proteins or genes, are being explored to dissect alternative angiogenesis mechanisms in tumor microenvironments.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2022)

添加到收藏夹

Article Medicine, General & Internal

Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition

Xiuhui Shi, Min Wang, Yuqing Zhang, Xingjun Guo, Mingyang Liu, Zhijun Zhou, Yan Zhao, Ruizhi He, Yang Gao, Yuhui Liu, Shutao Pan, Min Zhou, Chunle Zhao, Taoyuan Yin, Xu Li, Hebin Wang, Jingxuan Yang, Feng Zhu, Min Li, Renyi Qin

Summary: High expression levels of alpha-SMA and hypoxia markers are associated with poor prognosis in pancreatic cancer patients. Mechanistically, hypoxia induces HGF expression and secretion in PSC via HIF-1 alpha, which then activates Met and suppresses pancreatic cancer cell sensitivity to EGFR inhibitors. The combination of EGFR inhibitor and Met inhibitor shows promise for pancreatic cancer treatment based on the demonstrated signaling axis between PSC and cancer cells.

EBIOMEDICINE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Role of EREG/EGFR Pathway in Tumor Progression

Wan-Li Cheng, Po-Hao Feng, Kang-Yun Lee, Kuan-Yuan Chen, Wei-Lun Sun, Nguyen Van Hiep, Ching-Shan Luo, Sheng-Ming Wu

Summary: EREG activates EGFR signaling pathways to promote cancer progression and is associated with specific types of tumors and drug resistance. Tailored therapy should be chosen based on different oncogenic mutations and cellular contexts, such as combination treatment targeting EREG/EGFR and other driver mutations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Oncology

EGFR alterations in glioblastoma play a role in antitumor immunity regulation

Xiao-Peng Li, Zheng-Qian Guo, Bao-Feng Wang, Min Zhao

Summary: The most frequently altered gene in glioblastoma (GBM) is the epidermal growth factor receptor (EGFR), which plays a crucial role in tumor development and anti-tumor immune response. While current molecular targeted therapies against the EGFR signaling pathway and its downstream key molecules have not shown positive clinical outcomes in GBM. However, immunotherapies, especially immune checkpoint inhibitors, have demonstrated effective anti-tumor responses in various cancers. Yet, the clinical efficacy is limited in GBM patients with EGFR alterations, implying a potential involvement of EGFR signaling in tumor immune response. Recent studies suggest that EGFR alterations not only promote GBM cell proliferation but also affect immune components in the tumor microenvironment, leading to the recruitment of immunosuppressive cells and inhibition of T and NK cell activation. Furthermore, EGFR alterations upregulate the expression of immune suppressive molecules or cytokines. This review aims to explore the role of EGFR alterations in establishing an immunosuppressive tumor microenvironment and hopes to provide a theoretical basis for combining targeted EGFR inhibitors with immunotherapy for GBM.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer

Mofei Huang, Donghai Xiong, Jing Pan, Qi Zhang, Shizuko Sei, Robert H. Shoemaker, Ronald A. Lubet, Luis M. Montuenga, Yian Wang, Barbara S. Slusher, Ming You

Summary: JHU083, an orally active glutamine antagonist, effectively targets EGFR-driven lung tumorigenesis by increasing T cell infiltration and reducing immune suppressive cells, enhancing the efficacy of EVax.

ADVANCED SCIENCE (2022)

添加到收藏夹

Article Immunology

EGFR-targeted bacteriophage lambda penetrates model stromal and colorectal carcinoma tissues, is taken up into carcinoma cells, and interferes with 3-dimensional tumor formation

Haein Huh, Ding-Wen Chen, Marianna Foldvari, Roderick Slavcev, Jonathan Blay

Summary: Colorectal cancer and other solid tumors in adults present challenges for successful treatment due to the tumor microenvironment hindering conventional therapies and suppressing immune activities. Genetic approaches have the potential to interfere with local immunosuppression, thereby facilitating immune responses against cancer. Bacterial phages provide a novel means of delivering targeted genetic interventions into tumors.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice

Xinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K. Jain

Summary: Chimeric antigen receptor (CAR)-T cells have limited efficacy in treating glioblastoma (GBM) and other solid tumors due to the immunosuppressive tumor microenvironment (TME). Previous studies have shown that blocking vascular endothelial growth factor (VEGF) signaling can improve tumor vessel normalization and enhance the delivery of CD8+ T cells for effective immunotherapy. In this study, the researchers tested the hypothesis that anti-VEGF therapy can improve the delivery and efficacy of CAR-T cells in mice with GBM tumors, and found that it indeed enhanced CAR-T cell infiltration, delayed tumor growth, and prolonged survival.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review

Xiang Zou, Xi-Yu Tang, Zhong-Yuan Qu, Zhi-Wei Sun, Chen-Feng Ji, Yan-Jie Li, Shou-Dong Guo

Summary: The PDGF/PDGFR signaling pathway plays a crucial role in cancer, and targeting this pathway has become an effective strategy for cancer therapy with some progress in related research.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2022)

添加到收藏夹

Article Oncology

The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis

Yi Zheng, Shiying Hao, Cheng Xiang, Yaguang Han, Yanhong Shang, Qiang Zhen, Yiyi Zhao, Miao Zhang, Yan Zhang

Summary: This study found that high expression of SPP1 in patients with EGFR mutation in LUAD is associated with poor prognosis and immunosuppression, suggesting it may serve as a potential therapeutic target.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

WNT5A in tumor development and progression: A comprehensive review

Maura Lima Pereira Bueno, Sara Teresinha Olalla Saad, Fernanda Marconi Roversi

Summary: The investigation of tumor microenvironment is crucial for cancer diagnosis, prognosis, and treatment. WNT5A plays a critical role in tumorigenesis by regulating multiple signaling pathways and affecting cell growth, migration, and invasiveness.

BIOMEDICINE & PHARMACOTHERAPY (2022)

添加到收藏夹

Article Oncology

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

Lei Yang, Yun-Ting He, Song Dong, Xue-Wu Wei, Zhi-Hong Chen, Bo Zhang, Wei-Dong Chen, Xiao-Rong Yang, Fen Wang, Xue-Meng Shang, Wen-Zhao Zhong, Yi-Long Wu, Qing Zhou

Summary: This study investigates the immune microenvironment of EGFR-mutant and EGFR wild-type lung adenocarcinomas (LUADs) using single-cell transcriptome sequencing and multiplex immunohistochemistry. The results show that EGFR-mutant LUAD lacks CD8(+) tissue-resident memory (TRM) cells and has less crosstalk between T cells and other cell types compared to EGFR wild-type LUAD. These findings contribute to a better understanding of the immune landscape of EGFR-mutant LUAD at the single-cell level and suggest that the lack of CD8(+) TRM cells may be a key factor in the suppressive TME of EGFR-mutant LUAD.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Meng Qiao, Tao Jiang, Xinyu Liu, Shiqi Mao, Fei Zhou, Xuefei Li, Chao Zhao, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou

Summary: Although ICIs have significantly changed the treatment paradigm in advanced NSCLC, their clinical benefits are limited in patients with EGFR-mutated tumors due to the unique characteristics of the tumor microenvironment. The cancer immunogram can visualize the state of cancer-immune system interactions in EGFR-mutated NSCLC, helping identify subpopulations that may benefit from ICI treatment. Future strategies need to be developed to maximize the efficacy of ICI treatment in patients with EGFR-mutated NSCLC in the era of combination immunotherapies.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma

Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou

Summary: This study found that lung adenocarcinomas (LUAD) with EGFR-positive and ALK-positive had a suppressive tumor immune microenvironment (TIME) and were less responsive to immunotherapy. The TIME in patients with EGFR/ALK-positive LUAD brain metastases (BMs) was different from that in primary lung cancer. Evaluating the immune characteristics of LUAD BMs is important for clinical treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Endocrinology & Metabolism

Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential

Armel H. H. Nwabo Kamdje, Paul F. Seke Etet, Maulilio J. Kipanyula, Lorella Vecchio, Richard Tagne Simo, Alfred K. Njamnshi, Kiven E. Lukong, Patrice N. Mimche

Summary: The tumor microenvironment plays a role in tumorigenesis and drug resistance through the overexpression of insulin-like growth factor 1 (IGF-1). Anti-IGF therapies have shown potential in inhibiting cancer and overcoming chemotherapy drug resistance in preclinical studies, but toxicity and resistance are challenges in clinical trials.

FRONTIERS IN ENDOCRINOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma A systematic review and meta-analysis

Xiaohua Hong, Guangyao Wang, Guanglan Xu, Wei Shi, Tongbiao Wang, Zhen Rong, Chunmei Mo

Summary: The article evaluated the prognostic effect and clinical significance of epidermal growth factor receptor and its phosphorylated form (EGFR/p-EGFR) in nasopharyngeal carcinoma through a systematic review and meta-analysis. The results showed that EGFR overexpression could be used as a biomarker for poor overall survival (OS) and disease-free survival (DFS) in nasopharyngeal carcinoma, but not for progression-free survival (PFS) and distant metastasis-free survival (DMFS). The overexpression of p-EGFR was not associated with the prognosis of nasopharyngeal carcinoma patients.

MEDICINE (2022)

添加到收藏夹

Article Cell Biology

A conserved polybasic domain mediates plasma membrane targeting of Lgl and its regulation by hypoxia

Wei Dong, Xuejing Zhang, Weijie Liu, Yi-jiun Chen, Juan Huang, Erin Austin, Alicia M. Celotto, Wendy Z. Jiang, Michael J. Palladino, Yu Jiang, Gerald R. V. Hammond, Yang Hong

JOURNAL OF CELL BIOLOGY (2015)

添加到收藏夹

Meeting Abstract Oncology

Thromboxane A2 receptor controls migration and metastasis of triple-negative breast cancer cells

Yuanqin Zhang, Xuejing Zhang, Daotai Nie

CANCER RESEARCH (2016)

添加到收藏夹

Article Neurosciences

Altered long non-coding RNA transcriptomic profiles in brain microvascular endothelium after cerebral ischemia

J. Zhang, L. Yuan, X. Zhang, M. H. Hamblin, T. Zhu, F. Meng, Y. Li, Y. E. Chen, K. J. Yin

EXPERIMENTAL NEUROLOGY (2016)

添加到收藏夹

Article Neurosciences

Long Noncoding RNA Malat1 Regulates Cerebrovascular Pathologies in Ischemic Stroke

Xuejing Zhang, Xuelian Tang, Kai Liu, Milton H. Hamblin, Ke-Jie Yin

JOURNAL OF NEUROSCIENCE (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

The long noncoding RNA Malat1: Its physiological and pathophysiological functions

Xuejing Zhang, Milton H. Hamblin, Ke-Jie Yin

RNA BIOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Long Non-Coding RNA Malat1 Regulates Angiogenesis in Hindlimb Ischemia

Xuejing Zhang, Xuelian Tang, Milton H. Hamblin, Ke-Jie Yin

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

添加到收藏夹

Article Clinical Neurology

Noncoding RNAs and Stroke

Xuejing Zhang, Milton H. Hamblin, Ke-Jie Yin

NEUROSCIENTIST (2019)

添加到收藏夹

Article Neurosciences

Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair

Wei Cai, Tuo Yang, Huan Liu, Lijuan Han, Kai Zhang, Xiaoming Hu, Xuejing Zhang, Ke-Jie Yin, Yanqin Gao, Michael V. L. Bennett, Rehana K. Leak, Jun Chen

PROGRESS IN NEUROBIOLOGY (2018)

添加到收藏夹

Article Cell & Tissue Engineering

P53 Promotes Retinoid Acid-induced Smooth Muscle Cell Differentiation by Targeting Myocardin

Zhou Tan, Jingya Li, Xuejing Zhang, Xueqin Yang, Zunyi Zhang, Ke-Jie Yin, Huarong Huang

STEM CELLS AND DEVELOPMENT (2018)

添加到收藏夹

Meeting Abstract Oncology

G(alpha)12 is required for thromboxane A2 to regulate tumor cell motility

Babar Malik, Xuejing Zhang, Daotai Nie

CANCER RESEARCH (2011)

添加到收藏夹

Meeting Abstract Oncology

Thromboxane a2 receptor beta is induced by the epithelial to mesenchymal transition of breast cancer cells and contributes to breast cancer motility and metastasis

Xuejing Zhang

CANCER RESEARCH (2011)

添加到收藏夹

Meeting Abstract Oncology

Targeting Thromboxane A2 receptor (TP) to block breast cancer metastasis

Xuejing Zhang, Daotai Nie

CANCER RESEARCH (2012)

添加到收藏夹

Article Medicine, Research & Experimental

MicroRNA Biomarkers for Stroke

Xuejing Zhang, Ping Sun, Ke-Jie Yin

TRANSLATIONAL RESEARCH IN STROKE (2017)

添加到收藏夹

Meeting Abstract Oncology

Regulation of breast cancer metastasis by thromboxane A2 receptor signaling

Zhang Xuejing, Wang Man-Tzu, Chen Yakun, Tang Yong, Nie Daotai

CLINICAL & EXPERIMENTAL METASTASIS (2011)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.